Experienced in Mantle Cell Lymphoma (MCL)

Andreas Lohri

Liestal, BL, CH 
Experienced in Mantle Cell Lymphoma (MCL)
Liestal, BL, CH 
OverviewLocationsClinical Research

Overview

Andreas Lohri practices in Liestal, Switzerland. Mr. Lohri is rated as an Experienced expert by MediFind in the treatment of Mantle Cell Lymphoma (MCL). His top areas of expertise are Hodgkin Lymphoma, Follicular Lymphoma, Non-Hodgkin Lymphoma, and Mantle Cell Lymphoma (MCL).

His clinical research consists of co-authoring 25 peer reviewed articles and participating in 3 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 4 articles and participated in 1 clinical trial in the study of Mantle Cell Lymphoma (MCL).

Gender
Male

Locations

Liestal, BL, Switzerland
Other Locations
Kantonsspital St. Gallen
Sankt Gallen, SG, Switzerland
Bern, BE, Switzerland
Aarau, AG, Switzerland
Basel, BS, Switzerland

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

3 Clinical Trials

Adjuvant Aspirin Treatment in PIK3CA Mutated Colon Cancer Patients. A Randomized, Double-blinded, Placebo-controlled, Phase III Trial
Adjuvant Aspirin Treatment in PIK3CA Mutated Colon Cancer Patients. A Randomized, Double-blinded, Placebo-controlled, Phase III Trial
Enrollment Status: Terminated
Publish Date: May 16, 2025
Intervention Type: Drug
Study Drug: Aspirin
Study Phase: Phase 3
Rituximab With or Without Ibrutinib for Untreated Patients With Advanced Follicular Lymphoma in Need of Therapy. A Randomized, Double-blinded, SAKK and NLG Collaborative Phase II Trial.
Rituximab With or Without Ibrutinib for Untreated Patients With Advanced Follicular Lymphoma in Need of Therapy. A Randomized, Double-blinded, SAKK and NLG Collaborative Phase II Trial.
Enrollment Status: Terminated
Publish Date: March 13, 2024
Intervention Type: Drug
Study Drugs: Ibrutinib, Rituximab
Study Phase: Phase 2
Combination of Ibrutinib and Bortezomib Followed by Ibrutinib Maintenance to Treat Patients With Relapsed and Refractory Mantle Cell Lymphoma; a Multicenter Phase I/II Trial.
Combination of Ibrutinib and Bortezomib Followed by Ibrutinib Maintenance to Treat Patients With Relapsed and Refractory Mantle Cell Lymphoma; a Multicenter Phase I/II Trial.
Enrollment Status: Terminated
Publish Date: March 11, 2022
Intervention Type: Drug
Study Drugs: Ibrutinib, Bortezomib
Study Phase: Phase 1/Phase 2
View 2 Less Clinical Trials

25 Total Publications

Prolonged rituximab maintenance in follicular lymphoma patients: long-term results of the SAKK 35/03 randomized trial.
Prolonged rituximab maintenance in follicular lymphoma patients: long-term results of the SAKK 35/03 randomized trial.
Journal: Blood advances
Published: July 06, 2020

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Lohri's expertise for a condition
ConditionClose
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile